Results 31 to 40 of about 18,962 (231)

Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference

open access: yesClinical Medicine Insights: Endocrinology and Diabetes, 2011
Incretin-based therapies have been gaining much attention recently as a new class of therapeutics for type 2 diabetes worldwide. Among them, glucagon-like peptide-1 receptor agonist liraglutide has been rapidly increasing its global usage.
Daisuke Yabe, Yutaka Seino
doaj   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad   +4 more
wiley   +1 more source

Direct and indirect effects of liraglutide on hypothalamic POMC and NPY/AgRP neurons – Implications for energy balance and glucose control

open access: yesMolecular Metabolism, 2019
Objective: The long-acting glucagon-like peptide-1 receptor (GLP-1R) agonist, liraglutide, stimulates insulin secretion and efficiently suppresses food intake to reduce body weight.
Zhenyan He   +9 more
doaj   +1 more source

GLP‐1 Receptor Agonists and Endoscopy: Understanding Gastric Stasis, Aspiration Risk, and Contemporary Peri‐Procedural Guidance

open access: yesChronic Diseases and Translational Medicine, EarlyView.
Pharmacological mechanisms and physiologic effects of GLP‐1 receptor agonists relevant to peri‐endoscopic risk. ABSTRACT The global increase in obesity, type 2 diabetes mellitus (T2DM), and metabolic dysfunction‐associated steatotic liver disease (MASLD) has led to a higher use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) among patients ...
Junaid Beig   +7 more
wiley   +1 more source

A study on the therapeutic effect of liraglutide on chronic renal failure rats by down-regulating TGF-β1 and α-SMA

open access: yesLinchuang shenzangbing zazhi, 2020
Objective To explore the therapeutic effect of liraglutide on chronic renal failure(CRF)rats by down-regulating transforming growth factor-β1(TGF-β1)and α-smooth muscle actin(α-SMA).Methods Wistar rats were divided into sham group,chronic renal failure ...
CHEN Li   +3 more
doaj  

Research progress on the role of inflammatory mediators in the pathogenesis of epilepsy

open access: yesIbrain, Volume 11, Issue 1, Page 44-58, Spring 2025.
In the central nervous system, activated immune cells lead to the overproduction of inflammatory mediators through the corresponding signal pathway. Under the stimulation of inflammatory factors, neuroinflammation ultimately occurs. Overexpression of inflammatory mediators and activated immunocytes plays an important role in the emergence and ...
Yue Yu, Fei‐Ji Sun
wiley   +1 more source

Insulin Resistance: An Update on Biochemical and Pathophysiological Mechanisms and Impact on Various Diseases

open access: yesiNew Medicine, EarlyView.
ABSTRACT Insulin resistance is the biological phenomenon in which the human body's normal response to the metabolic hormone insulin is compromised. Insulin is a regulator of most of the essential metabolic steps in the body that control energy homoeostasis, so dysregulation leads to multiple diverse human diseases including, most prominently, Type 2 ...
Peter J. Little   +12 more
wiley   +1 more source

Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m²: A Post-hoc Analysis

open access: yesObesity Facts, 2017
Objective: To investigate whether the efficacy and safety of liraglutide 3.0 mg differed between two subgroups, BMI 27 to Methods: A post-hoc analysis of two 56-week, randomized, double-blind, placebo-controlled trials (SCALE Obesity and ...
Carel le Roux   +5 more
doaj   +1 more source

Multi‐omics biomarkers for intestinal infection and inflammation in inflammatory bowel disease: Current evidence, translational challenges, and diagnostic opportunities

open access: yesInterdisciplinary Medicine, EarlyView.
Prospective multi‐site cohorts, multi‐omics profiling, and computational analysis may help identify biomarker patterns across clinical settings in IBD and superimposed infections. With further mechanistic and clinical validation, these signals could support the development of practical multi‐analyte tools for more precise diagnosis and management ...
Ziyu Yang   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy